Cell Therapeutics, Inc. to Report Third Quarter Financial Results after Market on October 30, 2013

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

SEATTLE, Oct. 23, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its third quarter financial results on Wednesday, October 30, 2013, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT). Access to the event can be obtained as follows:

Wednesday, October 30, 2013
1:30 p.m. PDT/4:30 p.m. EDT/10:30 p.m. CEST
1-866-225- 8754 (domestic)
+1 480-629-9819 (international)

To access the live audio webcast or the subsequent archived recording, visit CTI’s website, www.celltherapeutics.com. Webcast and telephone replays of the conference call will be available at approximately two hours after completion of the call. Callers can access the replay by dialing 1-800-406-7325 (domestic) or +1 303-590-3030 (international). The access code for the replay is 4647208. The telephone replay will be available until Wednesday, November 6, 2013.

About Cell Therapeutics

Cell Therapeutics (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to sign up for email alerts and get RSS feeds, please visit www.CellTherapeutics.com.

Contacts:

Monique Greer
+1 206-272-4343
mgreer@ctiseattle.com

Ed Bell
+1 206.282.7100
ebell@ctiseattle.com

In Europe

CTI Life Sciences Limited, Milan Branch
Laura Villa
T: +39 02 89659706
E: lvilla@cti-lifesciences.com
CTI_EUInvestors@CTI-Lifesciences.com

SOURCE Cell Therapeutics, Inc.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC